ISSN: 2044-9038 (Print) 2044-9046 (Electronic)

Clinical Practice

Antirheumatic Drugs Impact Factor

Rheumatoid arthritis (RA) is the second most common type of arthritis, affecting about 1.5 million Americans. It’s an inflammatory disease that’s caused by an autoimmune condition. The disease occurs when your body attacks its own healthy joint tissues. This results in redness, inflammation, and pain. The main goal of RA drugs is to block inflammation. This helps prevent joint damage. Disease-modifying antirheumatic drugs (DMARDs) are a gaggle of medicines commonly utilized in people with atrophic arthritis. A number of these drugs also are utilized in treating other conditions like Marie-Strumpell disease, rheumatoid arthritis, and systemic LE. They can also be used to in the treatment of other disorders including connective tissue disease such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and Sjogren syndrome (SS), as well as in treatment of inflammatory myositis, vasculitis, uveitis, inflammatory bowel disease, and some types of cancers. Each DMARD has a unique mechanism of action ultimately interfering with critical pathways in the inflammatory cascade. Although many medications can be used in the treatment of RA, methotrexate is the most commonly used agent as an initial treatment. RA treatment is complicated with several factors playing a role in decision making, including disease activity and severity, comorbidities, and patient preference (including cost, route of administration and frequency of monitoring).    

High Impact List of Articles

Relevant Topics in Clinical